The Effect of Caffeine Therapy in Cardiovascular Stability in Preterm Neonates at Assiut University Children Hospital NICU

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-06-30

Study Completion Date

2027-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Preterm neonates younger than 37 weeks gestational age receiving caffeine therapy for apnea of prematurity in a NICU setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Feedings on Caffeine in Premature Infants

NCT02293824

Apnea of Prematurity Premature Newborn Caffeine

COMPLETED

The Caffeine Therapy in the Fetal to Neonatal Transition

NCT05454332

Mechanical Ventilation Complication Caffeine Ventilator Lung; Newborn

RECRUITING PHASE4

High Versus Low Dose of Caffeine for Apnea of Prematurity

NCT02103777

Apnea Preterm Infants

COMPLETED PHASE3

Early Versus Routine Caffeine Administration in Extremely Preterm Neonates

NCT01783561

Caffeine

COMPLETED PHASE4

Influence of Caffeine Therapy in Preterm Infants

NCT04376749

Caffeine; Sleep Disorder

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study population consists of 40 preterm neonates admitted to the Neonatal Intensive Care Unit at Assiut University Children Hospital. Inclusion criteria restrict participants to those with a gestational age below 37 weeks who are prescribed caffeine citrate therapy to manage apnea of prematurity. Neonates with major congenital anomalies or those requiring vasopressors at baseline are excluded. The cohort is monitored closely for cardiovascular parameters and adverse reactions related to caffeine administration. Demographic and clinical baseline data include prenatal risk factors, gestational and postnatal age, and birth weight. This focused population allows investigation of caffeine's impact on vulnerable cardiovascular physiology during early neonatal life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Neonates Apnea of Prematurity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Preterm neonates

Preterm neonates receiving standard caffeine citrate therapy for apnea of prematurity, including a loading dose of 20-25 mg/kg followed by maintenance dosing (5-10 mg/kg daily). Cardiovascular parameters and side effects are monitored longitudinally.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Preterm neonates with gestational age \<37 weeks
* Receiving caffeine therapy for apnea of prematurity
* Hemodynamically stable before caffeine initiation